Evaluating a Novel Human Fibrinogen Concentrate (BT524) for Congenital Fibrinogen Deficiency
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Excited to share our new publication evaluating a novel human fibrinogen concentrate (BT524) for the treatment of congenital fibrinogen deficiency!
This fibrinogen concentrate includes three independent virus inactivation and removal steps to ensure maximum viral safety.
In this prospective Phase I/III trial, BT524 was investigated in 27 patients (15 adults and 12 children) with congenital afibrinogenemia or severe hypofibrinogenemia:
- Single-dose administration (70 mg/kg) effectively increased fibrinogen antigen levels from undetectable to therapeutic levels
- Half-life: 67.9 hours (FiAg) and 60.3 hours (FiAc) – providing sustained hemostatic coverage
- Significant improvement in clot firmness (FIBTEM MCF +11.1 mm, p < 0.0001) within 1 hour
- Excellent safety profile – only one mild treatment-related adverse event (increased D-dimer), with no thromboembolic events, hypersensitivity reactions, or inhibitor development.
This new fibrinogen concentrate demonstrates excellent pharmacokinetics while providing an outstanding safety and tolerability profile across all age groups.
An important step forward for patients with this ultra-rare bleeding disorder, and a important improvement in the evolution of fibrinogen replacement therapy.
Congratulations to the study team, the co-authors and Biotest— more exciting work ahead!”
Read the full article here.
Article: Pharmacokinetics, Hemostatic Efficacy, and Safety of a New Human Fibrinogen Concentrate in Adult and Pediatric Patients with Congenital Fibrinogen Deficiency
Authors: Claudia Djambas Khayat, Amal El-Beshlawy, Balkis Meddeb, Abderrahim Khelif, Wolfgang Miesbach, Sonia Adolf, Heike Boehm, Silke Aigner, Salomon Abraha , Fabian Bohlaender, Joerg Schuettrumpf
Stay updated on all scientific advances Hemostasis Today.
-
Dec 7, 2025, 18:43ASH25 Day 2: Don’t Miss The Highlights
-
Dec 7, 2025, 17:01Abdul Mannan: How Do You Manage a Major Surgery When Blood Transfusion is Impossible?
-
Dec 7, 2025, 16:51Ahmed Bahi on Lina Merghani’s Critique of Early Withdrawal of Aspirin after PCI
-
Dec 7, 2025, 16:30Eloïse Laouenan Presents the Results of HEMOTHEPP-CHU Brest-GETBO Prospective Study
-
Dec 7, 2025, 16:21Jonathan Douxfils: Can We Estimate the VTE Risk of a Pill Before a Million Women Use It?
-
Dec 7, 2025, 16:06Pablo Corral on Why Early LDL-C Reduction Saves Lives
-
Dec 7, 2025, 15:53Paul Batty Congratulates Giulia Simini on Taking The Joint BSH-ASH Abstract Award
-
Dec 7, 2025, 15:35Federica Fogacci Presents The New ILEP Consensus Paper
-
Dec 7, 2025, 15:20Deep Molecular Modeling for Type 2A VWD from Omid Seidizadeh